The phase 3 REDEFINE 2 trial has been evaluating once-weekly subcutaneous CagriSema, a fixed dose combination of cagrilintide ...
Vivani Medical completed enrollment in its LIBERATE-1 trial, testing a six-month GLP-1 implant for weight management.
This came after Hetero Labs presented the BE study protocol, vide no. AZBE112405, Version No. 01, Dated 15.11.2024 and the ...
A mother revealed that she shed 165 lbs (approx. 75 kg) after using Ozempic. Amy Kane, from Chicago, shared her remarkable ...
NovoCare Pharmacy will provide all dose strengths of Wegovy at a reduced cost of $499 per month for cash-paying patients ...
The arrival of the MG Cyberster marks a significant moment in the story of the Chinese-owned brand. With the old Morris Garages MG having a rich history of sports cars, any flagship performance ...
Award-winning musician, Michael Trotter Jr. of The War and Treaty, critically acclaimed chef, Franklin Becker, and entrepreneur and salon owner, Maria, share how they manage their type 2 diabetes ...
Altimmune's pemvidutide shows promise in treating MASH and obesity, with upcoming Phase 2b results poised to shape its market impact. Read more on ALT stock here.
Rybelsus (semaglutide) and Ozempic (semaglutide ... 3 mg once per day 1.5 mg once per day Maintenance dosage 0.5 to 2 mg once per week 7 to 14 mg once per day 4 to 9 mg once per day Given by ...
In January and February, the FDA approved the NovoLog biosimilar MeriLog and issued an alert for diabetes-related smartphone device alerts. In January and February, the Food and Drug Administration ...
Ozempic (semaglutide) is prescribed to treat type 2 diabetes mellitus ... Ozempic also is available in a prefilled multidose pen that delivers 2 mg per injection. The initial recommended dose begins ...
Researchers found that among semaglutide users, the incidence rate of nonarteritic anterior ischemic optic neuropathy was 14.5 per 100,000 person-years. HealthDay News — For individuals with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results